KR101716522B1 - 날트렉손으로부터의 날메펜 히드로클로라이드의 제조 - Google Patents

날트렉손으로부터의 날메펜 히드로클로라이드의 제조 Download PDF

Info

Publication number
KR101716522B1
KR101716522B1 KR1020117028079A KR20117028079A KR101716522B1 KR 101716522 B1 KR101716522 B1 KR 101716522B1 KR 1020117028079 A KR1020117028079 A KR 1020117028079A KR 20117028079 A KR20117028079 A KR 20117028079A KR 101716522 B1 KR101716522 B1 KR 101716522B1
Authority
KR
South Korea
Prior art keywords
mthf
nalmefene
process according
naltrexone
hcl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020117028079A
Other languages
English (en)
Korean (ko)
Other versions
KR20120023704A (ko
Inventor
파베리 카를라 데
마우로 카사린
미켈레 브루세간
Original Assignee
하. 룬드벡 아크티에셀스카브
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43222172&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101716522(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 하. 룬드벡 아크티에셀스카브 filed Critical 하. 룬드벡 아크티에셀스카브
Publication of KR20120023704A publication Critical patent/KR20120023704A/ko
Application granted granted Critical
Publication of KR101716522B1 publication Critical patent/KR101716522B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
KR1020117028079A 2009-05-25 2010-05-21 날트렉손으로부터의 날메펜 히드로클로라이드의 제조 Expired - Fee Related KR101716522B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200900650 2009-05-25
DKPA200900650 2009-05-25
PCT/DK2010/050110 WO2010136039A1 (en) 2009-05-25 2010-05-21 Preparation of nalmefene hydrochloride from naltrexone

Publications (2)

Publication Number Publication Date
KR20120023704A KR20120023704A (ko) 2012-03-13
KR101716522B1 true KR101716522B1 (ko) 2017-03-14

Family

ID=43222172

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020117028079A Expired - Fee Related KR101716522B1 (ko) 2009-05-25 2010-05-21 날트렉손으로부터의 날메펜 히드로클로라이드의 제조

Country Status (35)

Country Link
US (1) US8598352B2 (enExample)
EP (1) EP2435439B8 (enExample)
JP (1) JP5794980B2 (enExample)
KR (1) KR101716522B1 (enExample)
CN (1) CN102459276B (enExample)
AR (1) AR076891A1 (enExample)
AU (1) AU2010252392B2 (enExample)
BR (1) BRPI1010975B1 (enExample)
CA (1) CA2763093C (enExample)
CL (1) CL2011002974A1 (enExample)
CO (1) CO6470832A2 (enExample)
CR (1) CR20110612A (enExample)
DK (1) DK2435439T3 (enExample)
DO (1) DOP2011000362A (enExample)
EA (1) EA019331B1 (enExample)
ES (1) ES2564006T3 (enExample)
GE (1) GEP20146190B (enExample)
HR (1) HRP20160110T1 (enExample)
HU (1) HUE026892T2 (enExample)
IL (1) IL216422A (enExample)
MA (1) MA33368B1 (enExample)
ME (1) ME02622B (enExample)
MX (1) MX2011012502A (enExample)
MY (1) MY158251A (enExample)
NZ (1) NZ596988A (enExample)
PL (1) PL2435439T3 (enExample)
RS (1) RS54599B1 (enExample)
SG (1) SG176205A1 (enExample)
SI (1) SI2435439T1 (enExample)
SM (1) SMT201600061B (enExample)
TN (1) TN2011000590A1 (enExample)
TW (1) TWI469985B (enExample)
UA (1) UA106752C2 (enExample)
WO (1) WO2010136039A1 (enExample)
ZA (1) ZA201108659B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI478928B (zh) 2010-06-11 2015-04-01 Rhodes Technologies 用於製備ｎ－烯丙基化合物之過渡金屬催化的製程及其用途
HRP20170379T1 (hr) 2010-11-05 2017-05-05 H. Lundbeck A/S Postupak proizvodnje naltreksona
CN103012416B (zh) * 2011-09-28 2015-07-01 辽宁海思科制药有限公司 一种盐酸纳美芬的制备方法
TWI560170B (en) 2011-12-06 2016-12-01 Lundbeck & Co As H Process for recovery of nalmefene hydrochloride
CN102584840A (zh) * 2011-12-28 2012-07-18 南京优科生物医药有限公司 一种制备纳美芬化合物的方法
WO2013164383A1 (en) 2012-05-03 2013-11-07 H. Lundbeck A/S Method for the manufacturing of naltrexone
US20140005217A1 (en) 2012-06-27 2014-01-02 H. Lundbeck A/S Nalmefene for reduction of alcohol consumption in specific target populations
CN103204859B (zh) * 2013-04-25 2015-12-02 四川海思科制药有限公司 一种盐酸纳美芬化合物及其制备方法
AR096851A1 (es) 2013-07-11 2016-02-03 H Lundbeck As Sales que no forman hidratos ni solvatos de nalmefeno
AU2014368548B2 (en) 2013-12-20 2019-09-19 H. Lundbeck A/S Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features
MX2016013889A (es) 2014-04-22 2017-03-09 Otsuka Pharma Co Ltd Medicamento.
CN104513251A (zh) * 2014-11-28 2015-04-15 安徽悦康凯悦制药有限公司 一种盐酸纳美芬的制备方法
US9757372B2 (en) * 2015-03-25 2017-09-12 Taiwanj Pharmaceuticals Co., Ltd. Toll-like receptor 4 antagonists and use in autoimmune liver diseases
RU2712232C1 (ru) * 2018-10-05 2020-01-27 Федеральное государственное унитарное предприятие "Научно-исследовательский институт гигиены, профпатологии и экологии человека" Федерального медико-биологического агентства Улучшенный способ получения налмефена из налтрексона
US10927121B1 (en) 2019-12-20 2021-02-23 Southwest Research Institute Technologies for removing residual solvent from nalmefene hydrochloride and producing crystalline nalmefene hydrochloride monohydrate, monosolvate, or crystalline nalmefene hydrochloride dihydrate
MX2023005055A (es) 2020-11-02 2023-07-14 Rhodes Tech Proceso de purificacion de noroximorfona.
WO2022165040A1 (en) 2021-01-28 2022-08-04 Rhodes Technologies Process for crystallizing nalmefene hydrochloride
CN117843650A (zh) * 2023-12-27 2024-04-09 南京海纳医药科技股份有限公司 一种盐酸纳美芬的精制方法
CN117986261B (zh) * 2024-04-02 2024-06-18 成都瑞尔医药科技有限公司 一种盐酸纳美芬母液的回收套用方法
CN119080788A (zh) * 2024-08-19 2024-12-06 南京海鲸药业股份有限公司 一种盐酸纳美芬杂质的去除监控系统及去除方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008104736A1 (en) * 2007-03-01 2008-09-04 Reckitt Benckiser Healthcare (Uk) Limited Improved medicinal compositions comprising buprenorphine and nalmefene

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4341764A (en) 1980-03-05 1982-07-27 Cutter Laboratories, Inc. Method of preparing fibronectin and antihemophilic factor
US4322426A (en) 1980-04-28 1982-03-30 E. I. Du Pont De Nemours And Company 17-Substituted-6-desoxy-7,8-dihydro-6α-methylnoroxymorphone narcotic antagonists
US4535157A (en) * 1983-11-01 1985-08-13 Key Pharmaceuticals, Inc. Process for making 6-desoxy-6-methylenenaloxone and 6-desoxy-6-methylenenaltrexone
US4751307A (en) 1985-01-17 1988-06-14 Mallinckrodt, Inc. Wittig-reaction processes
US4880813A (en) * 1988-07-22 1989-11-14 Baker Cummins Pharmaceuticals, Inc. Method of treatment for allergic rhinitis
US7687646B2 (en) 2006-03-28 2010-03-30 Azad Pharmaceutical Ingredients, Ag Polymorphic forms of olopatadine hydrochloride and methods for producing olopatadine and salts thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008104736A1 (en) * 2007-03-01 2008-09-04 Reckitt Benckiser Healthcare (Uk) Limited Improved medicinal compositions comprising buprenorphine and nalmefene

Also Published As

Publication number Publication date
TWI469985B (zh) 2015-01-21
EA019331B1 (ru) 2014-02-28
MY158251A (en) 2016-09-30
CL2011002974A1 (es) 2012-04-13
CN102459276A (zh) 2012-05-16
MX2011012502A (es) 2011-12-12
NZ596988A (en) 2013-03-28
CA2763093C (en) 2017-03-07
SMT201600061B (it) 2016-07-01
JP2012527489A (ja) 2012-11-08
WO2010136039A1 (en) 2010-12-02
CO6470832A2 (es) 2012-06-29
EA201171461A1 (ru) 2012-05-30
TN2011000590A1 (en) 2013-05-24
PL2435439T3 (pl) 2016-05-31
HUE026892T2 (en) 2016-07-28
UA106752C2 (uk) 2014-10-10
ME02622B (me) 2017-06-20
US8598352B2 (en) 2013-12-03
SI2435439T1 (sl) 2016-06-30
IL216422A (en) 2015-06-30
IL216422A0 (en) 2012-02-29
AU2010252392B2 (en) 2014-10-23
GEP20146190B (en) 2014-11-10
TW201043634A (en) 2010-12-16
CN102459276B (zh) 2016-09-21
MA33368B1 (fr) 2012-06-01
US20120123123A1 (en) 2012-05-17
AU2010252392A1 (en) 2012-01-12
SG176205A1 (en) 2011-12-29
CR20110612A (es) 2012-02-22
HRP20160110T1 (hr) 2016-03-11
RS54599B1 (sr) 2016-08-31
AR076891A1 (es) 2011-07-13
ZA201108659B (en) 2013-02-27
CA2763093A1 (en) 2010-12-02
BRPI1010975A2 (pt) 2015-10-20
DOP2011000362A (es) 2012-07-15
EP2435439A1 (en) 2012-04-04
ES2564006T3 (es) 2016-03-17
KR20120023704A (ko) 2012-03-13
JP5794980B2 (ja) 2015-10-14
BRPI1010975B1 (pt) 2021-08-24
EP2435439B1 (en) 2016-01-06
DK2435439T3 (en) 2016-02-29
EP2435439B8 (en) 2016-05-18

Similar Documents

Publication Publication Date Title
KR101716522B1 (ko) 날트렉손으로부터의 날메펜 히드로클로라이드의 제조
US8530495B2 (en) Nalmefene hydrochloride dihydrate
JP6215399B2 (ja) ナルトレキソンの製造方法
JP6086925B2 (ja) ナルメフェン塩酸塩の回収方法
HK1170728B (en) Preparation of nalmefene hydrochloride from naltrexone
HK1170728A (en) Preparation of nalmefene hydrochloride from naltrexone
KR101837795B1 (ko) 날트렉손의 제조 방법

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20200309

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20200309